Sagent Pharmaceuticals has launched Carboplatin Injection, an antineoplastic agent, in four preservative-free vial presentations. The product will be manufactured at Sagent’s SCP facility, a 300,000-sq.-ft. FDA- and cGMP-compliant sterile manufacturing facility located in Chengdu, China. The facility was designed initially to support the supply of chronically short oncology products. Carboplatin is the first product that Sagent will supply from this facility. Carboplatin Injection is indi...